Waters Corporation Welcomes King's College London into Waters Centers of Innovation Program

By Waters Corporation, PRNE
Tuesday, November 9, 2010

Aim is to Support the Drug Control Centre's Efforts to Develop Novel Analytical Methods for Sports Drug Testing and Toxicological Studies

MILFORD, Massachusetts, November 10, 2010 - Waters Corporation (NYSE: WAT) today welcomed into its Centers of
Innovation Program the Drug Control Centre within the Department of Forensic
Science and Drug Monitoring at King's College London.

In a symposium and ceremony held at King's College today, Waters
recognized researchers Prof. David Cowan and Dr. Norman Smith for their
ongoing work in the area of sports medicine and separation science.

Waters Centers of Innovation Program
is a new, corporate initiative which recognizes and supports the
efforts of scientists facilitating breakthroughs in health and life science
research, food safety, environmental protection, sports medicine and many
other areas.

"Our ongoing collaboration with Waters has helped us develop faster and
more sensitive analytical methods for sports drug testing. With their
innovation in LC-MS-MS, Waters has been a valuable partner in our efforts to
deter athletes from using drugs to enhance their performance," said Professor

Under the direction of Prof. Cowan, The King's College London Drug
Control Centre (www.kcl.ac.uk/schools/biohealth/research/drugcontrol)
will be responsible for all drug testing of athletes at the 2012 Olympic
Games. Prof. Cowan was also the Visiting Laboratory Director at the Salt Lake
City Winter Olympic Games, where the first positive result for novel
erythropoiesis-stimulating protein (NESP) was discovered, a substance used to
increase the delivery of oxygen. He was the senior external international
drug expert at the 2006 Turin Winter Olympic Games and 2008 Beijing Olympics,
a member of the IOC Medical Commission for the Sydney Olympic Games in 2000
and Vancouver Winter Olympic Games this year. He has served on a number of
national and international committees and has published extensively in the
field of pharmaceutical analysis especially as it relates to detecting drug
administration in sport.

In addition to performing research into Sports Drug Testing, Professor
Cowan's laboratory has taken a lead role in developing methods of analyzing
so-called "date rape drugs" that are typically undetectable in a victim's
blood as soon as 24 hours after administration. The LC-MS-MS methods his lab
has developed can now confirm the presence of previously unknown metabolites
for many days after the event, enhancing law enforcement efforts to establish
evidence of a crime.

Prof. Cowan's laboratory uses a Waters ACQUITY UPLC(R)
(www.waters.com/waters/nav.htm?locale=en_US&cid=10125009) System
combined with a tandem quadrupole mass spectrometer notable for its speed,
significantly shorter prep time and higher sensitivity.

"Professor Cowan and Dr. Norman Smith are doing exemplary research. Their
application of separations science combined with mass spectrometry is not
only innovative, their test methods are setting new standards of performance
for sports drug testing. We believe our Centers of Innovation Partnership
with them will lead to significant improvements in drug monitoring
methodology," said Tim Riley.

In a previous announcement
Waters highlighted its ongoing relationships with Prof. John Engen of
Northeastern University, Boston, Mass.; Prof. Jeremy Nicholson of Imperial
College London; Prof. Julie Leary of the University of California - Davis;
and with Prof. Jim Scrivens of the University of Warwick, Coventry, UK.

These leading scientists, in partnership with Waters, are using liquid
chromatography and mass spectrometry to take research down new paths and help
unlock the mysteries of science.

King's College London (www.kcl.ac.uk)

King's College London is one of the top 25 universities in the world
(2010 QS international world rankings), The Sunday Times 'University of the
Year 2010/11' and the fourth oldest in England. A research-led university
based in the heart of London, King's has nearly 23,000 students (of whom more
than 8,600 are graduate students) from nearly 140 countries, and some 5,500
employees. King's is in the second phase of a pounds Sterling 1 billion
redevelopment programme which is transforming its estate.

Waters Corporation (www.waters.com)

For more than 50 years, Waters Corporation (NYSE: WAT) has created
business advantages for laboratory-dependent organizations by delivering
practical and sustainable innovation to enable significant advancements in
such areas as healthcare delivery, environmental management, food safety, and
water quality worldwide.

Pioneering a connected portfolio of separations science, laboratory
information management, mass spectrometry and thermal analysis, Waters
technology breakthroughs and laboratory solutions provide an enduring
platform for customer success.

With revenue of US$1.5 billion in 2009 and 5,200 employees, Waters is
driving scientific discovery and operational excellence for customers

Waters and ACQUITY UPLC are trademarks of Waters Corporation.

Brian J. Murphy of Waters Corporation, Public Relations, +1-508-482-2614, brian_j_murphy at waters.com

will not be displayed